Jasper Therapeutics, Inc.
JSPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14 | $21 | $16 | $20 |
| G&A Expenses | $5 | $6 | $6 | $6 |
| SG&A Expenses | $5 | $6 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19 | $27 | $22 | $25 |
| Operating Income | -$19 | -$27 | -$22 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $1 | $1 |
| Pre-Tax Income | -$19 | -$27 | -$21 | -$24 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$19 | -$27 | -$21 | -$24 |
| % Margin | – | – | – | – |
| EPS | -1.13 | -1.74 | -1.41 | -1.62 |
| % Growth | 35.1% | -23.4% | 13% | – |
| EPS Diluted | -1.13 | -1.74 | -1.41 | -1.62 |
| Weighted Avg Shares Out | 17 | 15 | 15 | 15 |
| Weighted Avg Shares Out Dil | 17 | 15 | 15 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$19 | -$27 | -$22 | -$25 |
| % Margin | – | – | – | – |